Clinical Data for AMITIZA(R) Lubiprostone to be Presented

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Clinical Data for AMITIZA(R) Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting

BETHESDA, Md., Oct. 13, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq: SCMP ), a global biopharmaceutical company, today announced that clinical data for AMITIZA ® lubiprostone will be presented at the American College of Gastroenterology (ACG) 2014 Annual Scientific Meeting on Sunday, October 19, and Monday, October 20, at the Pennsylvania Convention Center in Philadelphia.

Poster Presentations

The following abstracts will be presented at ACG 2014:

Sunday, Oct. 19, from 3:30 p.m. to 7 p.m. EDT

  • Week 2 Response Predicts Durable Response to Lubiprostone in Patients With Chronic Idiopathic Constipation (Ayesha Akbar, MBChB (Hons), MRCP, PhD; Taryn Losch-Beridon, BS; Martin Wang, MS; Peter Lichtlen, MD, PhD)
    • Poster No: P499
       
  • Impact of Methadone Dose and Baseline Bowel Movement Frequency on Efficacy of Lubiprostone for Opioid-Induced Constipation (Byron Cryer, MD; Peter Lichtlen, MD, PhD; Martin Wang, MS; Taryn Losch-Beridon, BS)
    • Poster No: P500

Monday, Oct. 20, from 10:30 a.m. to 4 p.m. EDT

  • Effects of Lubiprostone, in Patients With Chronic Idiopathic and Opioid-Induced Constipation, on Serum Electrolytes and Markers of Renal Function (Satish S. C. Rao, MD, PhD, FACG; Egilius L. H. Spierings, MD, PhD; John F. Johanson, MD, MSc, FACP, FACG; Peter Lichtlen, MD, PhD; Sepideh Habibi, MD)
    • Poster no: P1102
       
  • Lubiprostone for Treatment of Opioid-Induced Constipation: Analysis of Influencing Factors (Taryn Losch-Beridon, BS; Peter Lichtlen, MD, PhD; Martin Wang, MS)
    • Poster No: P1105

About AMITIZA (lubiprostone)

AMITIZA (lubiprostone) is a prostone, and is a locally acting chloride channel activator, indicated in the United States for the treatment of chronic idiopathic constipation (CIC) in adults and opioid-induced constipation (OIC) in adults with chronic, non-cancer pain (24 mcg twice daily). The effectiveness in patients with OIC taking diphenylheptane opioids (e.g., methadone) has not been established. AMITIZA is also indicated in the U.S. for irritable bowel syndrome with constipation (IBS-C) (8 mcg twice daily) in women 18 years of age and older.

Important Safety Information

  • AMITIZA (lubiprostone) is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction. Patients with symptoms suggestive of mechanical gastrointestinal obstruction should be thoroughly evaluated by the treating healthcare provider (HCP) to confirm the absence of such an obstruction prior to initiating AMITIZA treatment.
  • Patients taking AMITIZA may experience nausea. If this occurs, concomitant administration of food with AMITIZA may reduce symptoms of nausea. Patients who experience severe nausea should inform their HCP.
  • AMITIZA should not be prescribed to patients that have severe diarrhea. Patients should be aware of the possible occurrence of diarrhea during treatment. Patients should be instructed to discontinue AMITIZA and inform their HCP if severe diarrhea occurs.
  • Patients taking AMITIZA may experience dyspnea within an hour of first dose. This symptom generally resolves within three hours, but may recur with repeat dosing. Patients who experience dyspnea should inform their HCP. Some patients have discontinued therapy because of dyspnea.
  • In clinical trials of AMITIZA (24 mcg twice daily vs placebo; N=1113 vs N=316, respectively) in patients with CIC, the most common adverse reactions (incidence > 4%) were nausea (29% vs 3%), diarrhea (12% vs < 1%), headache (11% vs 5%), abdominal pain (8% vs 3%), abdominal distension (6% vs 2%), and flatulence (6% vs 2%).
  • In clinical trials of AMITIZA (24 mcg twice daily vs. placebo; N=860 vs. N=632) in patients with OIC, the most common adverse reactions (incidence > 4%) were nausea (11% vs 5%) and diarrhea (8% vs 2%).
  • In clinical trials of AMITIZA (8 mcg twice daily vs. placebo; N=1011 vs. N=435, respectively) in patients with IBS-C the most common adverse reactions (incidence > 4%) were nausea (8% vs 4%), diarrhea (7% vs 4%), and abdominal pain (5% vs 5%).
  • Concomitant use of diphenylheptane opioids (e.g., methadone) may interfere with the efficacy of AMITIZA.
  • The safety of AMITIZA in pregnancy has not been evaluated in humans. Based on animal data, AMITIZA may cause fetal harm. AMITIZA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution should be exercised when AMITIZA is administered to a nursing woman. Advise nursing women to monitor infants for diarrhea.
  • Reduce the dosage in CIC and OIC patients with moderate and severe hepatic impairment. Reduce the dosage in IBS-C patients with severe hepatic impairment.

Please see the Full Prescribing Information here . For further information on AMITIZA, please visit www.sucampo.com/products .

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines to meet the major unmet medical needs of patients on a global basis. Sucampo has two marketed products – AMITIZA® and RESCULA® – and a pipeline of product candidates in clinical development. A global company, Sucampo is headquartered in Bethesda, Maryland, and has operations in Japan, Switzerland and the U.K. For more information, please visit www.sucampo.com .

The Sucampo logo is the registered trademark and the tagline, The Science of Innovation, is a pending trademark of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG. RESCULA is a registered trademark of R-Tech Ueno, Ltd, and has been licensed to Sucampo AG.

Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals).

Twitter    LinkedIn

Sucampo Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's most recent Form 8-K and 10-K, which Sucampo incorporates by reference.

Sucampo Pharmaceuticals, Inc. Silvia Taylor Senior Vice President, Investor Relations and Corporate Communications 1-240-223-3718

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 116

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 127

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 43

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 64

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 186

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Charter’s $1.5 Billion Tender Tests Debt Discipline

Updated Category News Views 176

Debt cleanup arrives with a hard ceiling Eight far-dated bond issues just got a very specific invitation from Charter Communications: hand them over for cash, but do not expect the company to write a blank check. Charter set final pricing on November 17 for tender offers covering up to $1.5 billion in aggregate consideration, excluding accrued interest and deal expenses....

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 226

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 57

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 193

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading

Top 5 Most Recently Viewed Articles

Butterfly Network and Rutgers Study Show Impact of POCUS

Updated Category News Views 129

Revolutionizing Hospital Care with POCUS Technology BURLINGTON, Mass. & NEW YORK-- Butterfly Network, Inc. (NYSE: BFLY), a pioneering digital health company, has launched a significant study in collaboration with Rutgers Robert Wood Johnson Medical School. This research emphasizes the transformative influence of point-of-care ultrasound (POCUS) technology on patient...

Continue Reading
Civista Bancshares Increases Quarterly Dividend to 17 Cents

Updated Category News Views 127

Civista Bancshares Boosts Quarterly Dividend Payments Civista Bancshares, Inc. (NASDAQ: CIVB), the financial cornerstone of Civista Bank, has made a noteworthy announcement regarding its quarterly dividends. The Board of Directors has approved a hike in the dividend to 17 cents per common share. This increment of 1 cent reflects the company's commitment to returning value...

Continue Reading
Argentinians Traveling Abroad for Cheaper Goods and Prices

Updated Category News Views 233

Argentinians Seeking Affordable Goods Abroad Amid rising domestic prices, it seems that many Argentinians are turning their eyes overseas in search of better deals on consumer goods. This trend has become evident as locals prioritize travel to countries like Brazil and Chile, where prices are significantly lower. The ongoing economic situation in Argentina, characterized...

Continue Reading
RomReal's Annual Report Insights and Audit Overview for 2024

Updated Category News Views 229

RomReal's Performance Overview for 2024 RomReal has been navigating a dynamic market landscape, with its annual report revealing insights into the company's financial health and operational resilience. The company has shown remarkable adaptability in the face of fluctuations within the industry, contributing to its performance in the 2024 fiscal year. This overview sheds...

Continue Reading
Microsoft's Flexible Work Policy: A New Era for Employees

Updated Category News Views 303

Microsoft rolled out a major statement back in 2024 that they're not gonna enforce a mandatory return-to-office unless they see productivity tank. Bigwigs at the company made it clear that for now, keeping things flexible is the name of the game. And why wouldn’t it be? With new hires flocking to companies that let them work from home, Microsoft knows they need to play...

Continue Reading